Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

HeartStitch® Inc. Announces CE Mark For CoAp Pro Mitral Valve Repair

HeartStitch
Posted on: 22 Apr 18

ZWICKAU, Germany, April 18, 2018 /PRNewswire/ -- HeartStitch® has received its CE Mark in the European Union for its device for treatment of mitral valve repair.   This approval will provide physicians the ability to remodel the leaflets of the mitral valve and reestablish proper coaptation.

The CoAp Pro expands HeartStitch's product line of cardiovascular devices, increasing the ability to provide surgeons and interventional cardiologists with a toolbox of solutions for treatment.

Prof. Dr. Achille Gaspardone, Director of Cardiology, Department of Medicine, Ospedale, S. Eugenio – ASL RMC, Rome Italy commented, "I am especially pleased to see HeartStitch® receive this approval, because it provides the ability to use suture to remodel the mitral valves rather than the need to place a prosthetic device in the leaflets. In my opinion it is a significant advancement to the treatment of Mitral Regurgitation.   Personally, I have seen the development of this device from its inception and have participated in the clinical testing, and with my extensive experience with the use of the NobleStitch™ EL for PFO closure it was a natural evolution for me to use this technology."

Dr. Michael Mullen, Chief Medical Officer of HeartStitch® remarked, "I have been working with the NobleStitch™ and HeartStitch® technologies for more than eight years, and I have seen the development of these devices as they have gone from prototype, to clinical testing, and finally to daily clinical use.   The recent advances to perform this procedure through normal venous access were made following the work we did testing in a clinical model. The feasibility of suture-based Mitral edge-to-edge 'Alfieri' stitching is now a reality."

Dru Dobbs, President of HeartStitch, Inc., stated, "With each new device we are continuing to grow HeartStitch to become the Global Leader in Cardiovascular solutions.   While the CoAp has an advanced design, it still retains the intuitive nature and ease-of-use which is the cornerstone of our cardiovascular device line.   In creating new suture-based solutions to treat cardiac disease we continue to provide physicians products that become their first choice to deliver the best outcomes for their patients."

Prof. Anthony Nobles, stated, "This CE Mark again shows that we have the ability to continue to grow our technology platform for many indications. The NobleStitch™ EL has played a significant part in our Company's ability to have physicians believe in percutaneous suture-based solutions for the treatment of structural heart disease. Doctors worldwide have been asking me for several years to use the NobleStitch™ EL for these indications."

Dirk Segers, Vice President of Sales and Marketing for HeartStitch® added, "The CoAp Pro will allow physicians to repair the leaflets of the mitral valve in a less invasive percutaneous and suture-based procedure.  European physicians are leading the way in their willingness to embrace our suture-based technology.  I find as I speak to physicians and distributors throughout Europe that they are now asking us to provide them with information on what our next product will be; they are looking to anticipate how they can expand our offerings to patient care.  HeartStitch® continues to define the new approach to cardiac interventions."

About HeartStitch®
HeartStitch® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace.  HeartStitch® is focused on the innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.  HeartStitch® currently markets the NobleStitch™ EL under license the NobleStitch™ EL device for cardiovascular suturing and PFO closure. HeartStitch™ develops new structural heart technologies through its international innovation development teams in California, Kazakhstan and Germany.

HeartStitch® is a registered trademark of HeartStitch, Inc.

HeartStitch® Access Pro
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, and 8709020.

HeartStitch® CoAp Pro
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, 8709020, and 8771296.

NobleStitch™ EL
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.

For more on HeartStitch® visit www.HeartStitch.com

For more information, please contact:

USA

In Kazakhstan

Dru Dobbs

Kazbek Aubakirov

P. +1 714 427 6348

P. +7 777 5009005

F. +1 714 427 6343

kaubakirov@HeartStitch.com

ddobbs@HeartStitch.com

 

Media Contact

 

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 22/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.